Skip to content

A prospective non-randomized controlled clinical study evaluating the effectiveness and safety of Yuye Jiedu Granules in the treatment of children with influenza wind-heat and dampness syndrome

A prospective non-randomized controlled clinical study evaluating the effectiveness and safety of Yuye Jiedu Granules in the treatment of children with influenza wind-heat and dampness syndrome

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040449
Enrollment
Unknown
Registered
2020-11-28
Start date
2020-11-26
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Childhood influenza

Interventions

Sponsors

The First Teaching Hospital of Tianjin University of TCM
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 13 Years

Inclusion criteria

Inclusion criteria: (1) Meet the clinical diagnostic criteria for influenza in children, and the rapid influenza antigen test (colloidal gold immunochromatographic method) is positive; (2) Meet the TCM syndrome differentiation standard of wind-heat and dampness; (3) Aged from 1 to 13 years old (=8 years old) jointly signs the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Suffering from pharyngeal conjunctival fever, herpetic angina, purulent tonsillitis, etc.; (2) Influenza complications such as sinusitis, otitis media, bronchitis, pneumonia, nervous system damage, heart damage, myositis and rhabdomyolysis, septic shock have occurred; (3) Severe or critical cases of influenza; (4) Antiviral drugs have been used within 48 hours before this visit; (5) Have received influenza vaccine within 12 months before the start of the test; (6) Receiving steroid therapy or other immunosuppressive therapy systemically; (7) History of epilepsy or high fever convulsion; (8) Patients with severe malnutrition, rickets, and serious primary diseases of the heart, brain, liver, kidney and hematopoietic system; (9) Allergic to test drugs; (10) According to the judgment of the investigator, there are other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as unstable living environment, inconvenient transportation, etc. that may easily cause loss to follow-up.

Design outcomes

Primary

MeasureTime frame
Clinical recovery rate;TCM syndrome curative effect (effective rate);

Countries

China

Contacts

Public ContactSiyuan Hu

The First Teaching Hospital of Tianjin University of TCM

husiyuan1963@sina.com+86 022-27432222

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026